NLS Pharmaceutics Ltd (NLSP)
0.1341
0.00 (0.00%)
USD |
NASDAQ |
May 02, 10:27
NLS Pharmaceutics Total Liabilities (Quarterly): 6.557M for June 30, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2023 | 6.557M |
| June 30, 2023 | 6.557M |
| December 31, 2022 | 5.996M |
| June 30, 2022 | 6.100M |
| June 30, 2022 | 6.100M |
| December 31, 2021 | 5.222M |
| June 30, 2021 | 4.020M |
| June 30, 2021 | 4.020M |
| Date | Value |
|---|---|
| December 31, 2020 | 10.20M |
| June 30, 2020 | 7.974M |
| June 30, 2020 | 7.974M |
| December 31, 2019 | 6.867M |
| June 30, 2019 | 5.571M |
| June 30, 2019 | 5.571M |
| December 31, 2018 | 8.959M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
4.020M
Minimum
Jun 2021
10.20M
Maximum
Dec 2020
6.337M
Average
6.100M
Median
Jun 2022
Total Liabilities (Quarterly) Benchmarks
| AC Immune SA | 26.40M |
| CRISPR Therapeutics AG | 346.77M |
| Addex Therapeutics Ltd | 4.163M |
| Molecular Partners AG | 26.10M |
| MoonLake Immunotherapeutics | 13.05M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.270M |
| Shareholders Equity (Quarterly) | -4.287M |